All In Biotech

Drug Trial Radar · NCT07940647

A Safety and Tolerability Study of HJB647 in Adult Participants With Uncontrolled Hypertension

A Randomized, Participant- and Investigator-blinded, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of HJB647 in Adult Participants With Uncontrolled Hypertension.

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Nov 23, 2026

Primary completion

Nov 5, 2027

Study completion Nov 5, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at different doses in participants with uncontrolled hypertension (uHTN)

Conditions

  • Uncontrolled Hypertension

Interventions

  • HJB647Drug

    HJB647 oral capsules administered in adult participants with uncontrolled hypertension

  • PlaceboDrug

    Matching placebo capsules administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: From first dose through the arm-specific end-of-study visit, up to Day 85

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.